Concepts (90)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypertension, Pulmonary | 3 | 2024 | 464 | 1.660 |
Why?
|
| Myocardial Perfusion Imaging | 5 | 2014 | 57 | 0.900 |
Why?
|
| Purines | 5 | 2014 | 113 | 0.890 |
Why?
|
| Norwood Procedures | 1 | 2024 | 105 | 0.800 |
Why?
|
| Pyrazoles | 5 | 2014 | 330 | 0.750 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2024 | 339 | 0.730 |
Why?
|
| Scimitar Syndrome | 1 | 2022 | 52 | 0.720 |
Why?
|
| Hypoplastic Left Heart Syndrome | 1 | 2024 | 271 | 0.700 |
Why?
|
| Pulmonary Veins | 1 | 2022 | 167 | 0.670 |
Why?
|
| Palliative Care | 1 | 2024 | 457 | 0.660 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 3 | 2014 | 106 | 0.580 |
Why?
|
| Heart Defects, Congenital | 2 | 2022 | 1867 | 0.570 |
Why?
|
| Exercise Test | 5 | 2016 | 256 | 0.550 |
Why?
|
| Aminophylline | 4 | 2014 | 8 | 0.530 |
Why?
|
| Turner Syndrome | 1 | 2017 | 45 | 0.530 |
Why?
|
| Physical Endurance | 1 | 2016 | 47 | 0.510 |
Why?
|
| Physical Fitness | 1 | 2016 | 93 | 0.500 |
Why?
|
| Adenosine A2 Receptor Agonists | 4 | 2014 | 12 | 0.450 |
Why?
|
| Down Syndrome | 1 | 2017 | 230 | 0.440 |
Why?
|
| Diarrhea | 2 | 2012 | 333 | 0.420 |
Why?
|
| Dizziness | 1 | 2012 | 27 | 0.390 |
Why?
|
| Cardiac Surgical Procedures | 2 | 2021 | 1165 | 0.380 |
Why?
|
| Abnormalities, Multiple | 1 | 2017 | 983 | 0.350 |
Why?
|
| Heart Failure | 1 | 2021 | 2386 | 0.270 |
Why?
|
| Infant, Newborn | 4 | 2024 | 8566 | 0.250 |
Why?
|
| Kidney Failure, Chronic | 2 | 2014 | 903 | 0.240 |
Why?
|
| Postoperative Period | 1 | 2024 | 333 | 0.210 |
Why?
|
| Child | 7 | 2024 | 25823 | 0.200 |
Why?
|
| Out-of-Hospital Cardiac Arrest | 1 | 2024 | 98 | 0.200 |
Why?
|
| Child, Preschool | 4 | 2024 | 14853 | 0.180 |
Why?
|
| Pulmonary Surfactants | 1 | 2021 | 44 | 0.170 |
Why?
|
| Humans | 15 | 2024 | 132336 | 0.170 |
Why?
|
| Respiratory Distress Syndrome, Newborn | 1 | 2021 | 82 | 0.170 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2024 | 333 | 0.170 |
Why?
|
| Cardiovascular System | 1 | 2021 | 107 | 0.160 |
Why?
|
| Retrospective Studies | 4 | 2024 | 17363 | 0.150 |
Why?
|
| Infant, Premature, Diseases | 1 | 2021 | 252 | 0.150 |
Why?
|
| Prospective Studies | 2 | 2024 | 6540 | 0.150 |
Why?
|
| Length of Stay | 1 | 2024 | 1378 | 0.150 |
Why?
|
| Cardiac Catheterization | 1 | 2022 | 665 | 0.140 |
Why?
|
| Intensive Care Units, Pediatric | 1 | 2021 | 466 | 0.140 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2024 | 657 | 0.140 |
Why?
|
| Registries | 1 | 2024 | 1585 | 0.130 |
Why?
|
| Male | 9 | 2024 | 65054 | 0.130 |
Why?
|
| Female | 9 | 2024 | 70788 | 0.120 |
Why?
|
| Biomarkers | 1 | 2024 | 3389 | 0.110 |
Why?
|
| Vasodilator Agents | 2 | 2014 | 207 | 0.110 |
Why?
|
| Hyperemia | 1 | 2014 | 35 | 0.110 |
Why?
|
| Pandemics | 1 | 2021 | 1188 | 0.100 |
Why?
|
| Double-Blind Method | 4 | 2014 | 1647 | 0.100 |
Why?
|
| United States | 2 | 2021 | 11628 | 0.090 |
Why?
|
| Echocardiography | 1 | 2017 | 1125 | 0.090 |
Why?
|
| Exercise | 1 | 2016 | 865 | 0.080 |
Why?
|
| Risk Factors | 2 | 2016 | 10910 | 0.080 |
Why?
|
| Body Mass Index | 1 | 2016 | 1707 | 0.080 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2012 | 277 | 0.080 |
Why?
|
| Abdominal Pain | 1 | 2012 | 314 | 0.080 |
Why?
|
| Infant | 2 | 2024 | 13192 | 0.080 |
Why?
|
| Pilot Projects | 1 | 2012 | 1454 | 0.070 |
Why?
|
| Cardiotonic Agents | 3 | 2014 | 135 | 0.070 |
Why?
|
| Cross-Sectional Studies | 1 | 2016 | 3744 | 0.070 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2012 | 1247 | 0.070 |
Why?
|
| Comorbidity | 1 | 2012 | 1605 | 0.070 |
Why?
|
| Adolescent | 3 | 2024 | 20552 | 0.060 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2014 | 803 | 0.060 |
Why?
|
| Incidence | 1 | 2012 | 3361 | 0.060 |
Why?
|
| Middle Aged | 5 | 2014 | 28888 | 0.060 |
Why?
|
| Purinergic P1 Receptor Antagonists | 1 | 2013 | 3 | 0.050 |
Why?
|
| Placebo Effect | 2 | 2014 | 24 | 0.050 |
Why?
|
| Administration, Intravenous | 1 | 2013 | 159 | 0.050 |
Why?
|
| Risk | 1 | 2013 | 763 | 0.040 |
Why?
|
| Surface-Active Agents | 1 | 2021 | 30 | 0.040 |
Why?
|
| Sex Factors | 1 | 2013 | 1353 | 0.040 |
Why?
|
| Survival Rate | 1 | 2024 | 2187 | 0.040 |
Why?
|
| Age Factors | 1 | 2013 | 2931 | 0.030 |
Why?
|
| Heart | 1 | 2021 | 699 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2014 | 747 | 0.020 |
Why?
|
| Image Enhancement | 1 | 2014 | 174 | 0.020 |
Why?
|
| Hospitalization | 1 | 2021 | 1894 | 0.020 |
Why?
|
| Gastrointestinal Tract | 1 | 2014 | 238 | 0.020 |
Why?
|
| Adenosine A2 Receptor Antagonists | 1 | 2012 | 10 | 0.020 |
Why?
|
| Premedication | 1 | 2012 | 42 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 2012 | 247 | 0.020 |
Why?
|
| Glomerular Filtration Rate | 1 | 2014 | 536 | 0.020 |
Why?
|
| Aged | 2 | 2014 | 21379 | 0.020 |
Why?
|
| Drug Interactions | 1 | 2012 | 246 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2014 | 2145 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 3022 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2012 | 13016 | 0.010 |
Why?
|
| Adult | 1 | 2014 | 31618 | 0.010 |
Why?
|
MORALES DEMORI's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(90)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(12)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People who are also in this person's primary department.
Explore
_